Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents

Current Medicinal Chemistry

Volumn 20, Issue 5, 2013, Pages 694-709

  Pogorelcnik B ^a   Perdih, A ^a   Solmajer, T ^a  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

Anticancer agents; ATP binding site; Catalytic inhibitors; DNA topoisomerase II ; Drug design; ICRF 187 inhibitor; Medicinal chemistry

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; DOUBLE STRANDED DNA; RAZOXANE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CHROMOSOME; CHROMOSOME SEGREGATION; CRYSTAL STRUCTURE; DNA CLEAVAGE; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DNA TRANSCRIPTION; DRUG DESIGN; ENZYME ACTIVITY; ENZYME BINDING; HYDROLYSIS; SEPARATION TECHNIQUE;

EID: 84877965129     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804999402     Document Type: Article

References (106)

1. Bates, A.D.; Maxwell, A. DNA topology: topoisomerases keep it simple. Curr. Biol., 1997, 7, 778-781.
2. Nitiss, J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Bba-Gene Struct. Expr., 1998, 1400, 63-81.
3. Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell. Biol., 2002, 3, 430-440.
4. Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer, 2009, 9, 327-337.
5. Berger, J.M. Structure of DNA topoisomerases. Bba-Gene Struct. Expr., 1998, 1400, 3-18.
6. Champoux, J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem., 2001, 369-413.
7. Schoeffler, A.J.; Berger, J.M. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys., 2008, 41, 41-101.
8. Sharma, A.; Mondragon, A. DNA Topoisomerases. Curr. Opin. Struct. Biol., 1995, 5, 39-47.
9. Corbett, K.D.; Berger, J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 2004, 33, 95-118.
10. Berger, J.M. Type II DNA topoisomerases. Curr. Opin. Struct. Bio.l, 1998, 8, 26-32.
11. Vélez-Cruz, R.; Osheroff, N. In Encyclopedia of Biological Chemistry. Editors-in-Chief: William, J.L.; Lane, M.D., Eds.; Elsevier: New York, 2004, pp 806-811.
12. Fortune, J.M.; Osheroff, N. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology, Vol 64, 2000, 64, 221-253.
13. McClendon, A.K.; Rodriguez, A.C.; Osheroff, N. Human topoisomerase II alpha rapidly relaxes positively supercoiled DNA -Implications for enzyme action ahead of replication forks. J. Biol. Chem., 2005, 280, 39337-39345.
14. Berger, J.M.; Gamblin, S.J.; Harrison, S.C.; Wang, J.C. Structure and mechanism of DNA topoisomerase II. Nature, 1996, 379, 225-232.
15. Berger, J.M.; Fass, D.; Wang, J.C.; Harrison, S.C. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 7876-7881.
16. Watt, P.M.; Hickson, I.D. Structure and Function of Type-Ii DNA Topoisomerases. Biochem. J., 1994, 303, 681-695.
17. Chene, P. ATPases as drug targets: Learning from their structure. Nat. Rev. Drug Discov., 2002, 1, 665-673.
18. Dutta, R.; Inouye, M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci., 2000, 25, 24-28.
19. Chikamori, K.; Grozav, A.G.; Kozuki, T.; Grabowski, D.; Ganapathi, R.; Ganapathi, M.K. DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Curr. Cancer Drug Tar., 2010, 10, 758-771.
20. Classen, S.; Olland, S.; Berger, J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 (vol 100, pg 10629, 2003). Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 14510-14510.
21. Wei, H.; Ruthenburg, A.J.; Bechis, S.K.; Verdine, G.L. Nucleotidedependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J. Biol. Chem., 2005, 280, 37041-37047.
22. Dong, K.C.; Berger, J.M. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature, 2007, 450, 1201-1204.
23. Wendorff, T.J.; Schmidt, B.H.; Heslop, P.; Austin, C.A.; Berger, J.M. The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage. J. Mol. Biol., 2012, 424, 109-124.
24. Wu, C.C.; Li, T.K.; Farh, L.; Lin, L.Y.; Lin, T.S.; Yu, Y.J.; Yen, T.J.; Chiang, C.W.; Chan, N.L. Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide. Science, 2011, 333, 459-462.
25. Schmidt, B.H.; Osheroff, N.; Berger, J.M. Structure of a topoisomerase IIDNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat. Struct. Mol. Biol., 2012, 19, 1147-1154.
26. Delano, W. The PyMOL Molecular Graphics System. http://www.pymol.org.
27. Roca, J.; Wang, J.C. The Capture of a DNA Double Helix by an Atp-Dependent Protein Clamp -A Key Step in DNA Transport by Type-Ii DNA Topoisomerases. Cell, 1992, 71, 833-840.
28. Roca, J.; Berger, J.M.; Harrison, S.C.; Wang, J.C. DNA transport by a type II topoisomerase: Direct evidence for a two-gate mechanism. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 4057-4062.
29. Roca, J.; Wang, J.C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 1994, 77, 609-616.
30. Wang, J.C. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys., 1998, 31, 107-144.
31. Burden, D.A.; Osheroff, N. Mechanism of action of eukaryotic topo isomerase II and drugs targeted to the enzyme. Bba-Gene Struct. Expr., 1998, 1400, 139-154.
32. Baird, C.L.; Gordon, M.S.; Andrenyak, D.M.; Marecek, J.F.; Lindsley, J.E. The ATPase reaction cycle of yeast DNA topoisomerase II -Slow rates of ATP resynthesis and P-i release. J. Biol. Chem., 2001, 276, 27893-27898.
33. Baird, C.L.; Harkins, T.T.; Morris, S.K.; Lindsley, J.E. Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 13685-13690.
34. Skouboe, C.; Bjergbaek, L.; Oestergaard, V.H.; Larsen, M.K.; Knudsen, B.R.; Andersen, A.H. A human topoisomerase II alpha heterodimer with only one ATP binding site can go through successive catalytic cycles. J. Biol. Chem., 2003, 278, 5768-5774.
35. Osheroff, N.; Shelton, E.R.; Brutlag, D.L. DNA Topoisomerase-Ii from Drosophila-Melanogaster -Relaxation of Supercoiled DNA. J. Biol. Chem., 1983, 258, 9536-9543.
36. Larsen, A.K.; Eseargueil, A.E.; Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther., 2003, 99, 167-181.
37. Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 2009, 9, 338-350.
38. Corbett, A.H.; Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 1993, 6, 585-597.
39. Pommier, Y.; Leo, E.; Zhang, H.L.; Marchand, C. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs. Chem. Biol., 2010, 17, 421-433.
40. Topcu, Z. DNA topoisomerases as targets for anticancer drugs. J. Clin. Pharm. Ther., 2001, 26, 405-416.
41. Walker, J.V.; Nitiss, J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest., 2002, 20, 570-589.
42. Wilstermann, A.M.; Osheroff, N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem., 2003, 3, 321-338.
43. McClendon, A.K.; Osheroff, N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res.-Fund. Mol. M., 2007, 623, 83-97.
44. Robert, J.; Larsen, A.K. Drug resistance to topoisomerase II inhibitors. Biochimie, 1998, 80, 247-254.
45. Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Bba-Gene Struct. Expr., 1998, 1400, 155-171.
46. Andoh, T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topo isomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie, 1998, 80, 235-246.
47. Hande, K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Bba-Gene Struct. Expr., 1998, 1400, 173-184.
48. Oestergaard, V.H.; Bjergbaek, L.; Skouboe, C.; Giangiacomo, L.; Knudsen, B.R.; Andersen, A.H. The transducer domain is important for clamp operation in human DNA topoisomerase II alpha. J. Biol. Chem., 2004, 279, 1684-1691.
49. Bendsen, S.; Oestergaard, V.H.; Skouboe, C.; Brinch, M.; Knudsen, B.R.; Andersen, A.H. The QTK Loop Is Essential for the Communication between the N-Terminal ATPase Domain and the Central Cleavage-Ligation Region in Human Topoisomerase II alpha. Biochemistry, 2009, 48, 6508-6515.
50. Laponogov, I.; Pan, X.S.; Veselkov, D.A.; McAuley, K.E.; Fisher, L.M.; Sanderson, M.R. Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases. Plos One, 2010, 5, e11338-.
51. Laponogov, I.; Sohi, M.K.; Veselkov, D.A.; Pan, X.S.; Sawhney, R.; Thompson, A.W.; McAuley, K.E.; Fisher, L.M.; Sanderson, M.R. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol., 2009, 16, 667-669.
52. Jensen, L.H.; Thougaard, A.V.; Grauslund, M.; Sokilde, B.; Carstensen, E.V.; Dvinge, H.K.; Scudiero, D.A.; Jensen, P.B.; Shoemaker, R.H.; Sehested, M. Substituted purine analogs define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res., 2005, 65, 7470-7477.
53. Jensen, L.H.; Liang, H.; Shoemaker, R.; Grauslund, M.; Sehested, M.; Hasinoff, B.B. A three-dimensional quantitative structure-Activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol. Pharmacol., 2006, 70, 1503-1513.
54. Chene, P.; Rudloff, J.; Schoepfer, J.; Furet, P.; Meier, P.; Qian, Z.; Schlaeppi, J.M.; Schmitz, R.; Radimerski, T. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analog. BMC Chem. Biol., 2009, 9, 1.
55. Furet, P.; Schoepfer, J.; Radimerski, T.; Chene, P. Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. Bioorg. Med. Chem. Lett., 2009, 19, 4014-4017.
56. Baenteli, R.C., P.; Collingwood, S. P.; Furet, P., Meiler, P.; Schoepfer, J. Use of 9H-purine-2,6-diamine derivates in the treatment of proliferate diseases and novel 9H-purine-2,6-diamine derivates PCT Int: Appl. WO2005/097135 April 5, 2004.
57. Wang, P.; Leung, C.H.; Ma, D.L.; Lu, W.; Che, C.M. Organoplatinum(H) Complexes with Nucleobase Motifs as Inhibitors of Human Topoisomerase II Catalytic Activity. Chem.-Asian J., 2010, 5, 2271-2280.
58. Gandhi, V.; Ayres, M.; Halgren, R.G.; Krett, N.L.; Newman, R.A.; Rosen, S.T. 8-chloro-cAMP and 8-chloro-Adenosine act by the same mechanism in multiple myeloma cells. Cancer Res., 2001, 61, 5474-5479.
59. Yang, S.Y.; Jia, X.Z.; Feng, L.Y.; Li, S.Y.; An, G.S.; Ni, J.H.; Jia, H.T. Inhibition of topoisomerase II by 8-chloro-Adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-Adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol., 2009, 77, 433-443.
60. Huang, H.; Chen, Q.; Ku, X.; Meng, L.H.; Lin, L.P.; Wang, X.; Zhu, C.H.; Wang, Y.; Chen, Z.; Li, M.; Jiang, H.L.; Chen, K.X.; Ding, J.; Liu, H. A Series of alpha-Heterocyclic Carboxaldehyde Thiosemicarbazones Inhibit Topoisomerase II alpha Catalytic Activity. J. Med. Chem., 2010, 53, 3048-3064.
61. Baviskar, A.T.; Madaan, C.; Preet, R.; Mohapatra, P.; Jain, V.; Agarwal, A.; Guchhait, S.K.; Kundu, C.N.; Banerjee, U.C.; Bharatam, P.V. N-Fused Imidazoles As Novel Anticancer Agents That Inhibit Catalytic Activity of Topoisomerase II alpha and Induce Apoptosis in G1/S Phase. J. Med. Chem., 2011, 54, 5013-5030.
62. Jun, K.Y.; Lee, E.Y.; Jung, M.J.; Lee, O.H.; Lee, E.S.; Choo, H.Y.P.; Na, Y.; Kwon, Y. Synthesis, biological evaluation, and molecular docking study of 3-(3 '-heteroatom substituted-2 '-hydroxy-1 '-propyloxy) xanthone analogs as novel topoisomerase II alpha catalytic inhibitor. Eur. J. Med. Chem., 2011, 46, 1964-1971.
63. Feng, C.; Wang, L.; Yan, Y.; Liu, J.; Li, S. Synthesis and antitumor evaluation of some 1,3,4-oxadiazole-2(3H)-thione and 1,2,4-triazole-5(1H)-thione derivatives. Med. Chem. Res., 2010, 1-6.
64. Wang, B.; Miao, Z.W.; Wang, J.; Chen, R.Y.; Zhang, X.D. Synthesis and biological evaluation of novel naphthoquinone fused cyclic aminoalkyl phosphonates and aminoalkylphosphonic monoester. Amino Acids, 2008, 35, 463-468.
65. Ma, Y.; Wang, J.G.; Wang, B.; Li, Z.M. Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic alpha-Aminophosphonates that act as novel topoisomerase II inhibitors. J. Mol. Model., 2011, 17, 1899-1909.
66. Hu, C.X.; Zuo, Z.L.; Xiong, B.; Ma, J.G.; Geng, M.Y.; Lin, L.P.; Jiang, H.L.; Ding, J. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol. Pharmacol., 2006, 70, 1593-1601.
67. Gui, M.; Shi, D.K.; Huang, M.; Zhao, Y.; Sun, Q.M.; Zhang, J.; Chen, Q.; Feng, J.M.; Liu, C.H.; Li, M.; Li, Y.X.; Geng, M.; Ding, J. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIalpha. Invest. New Drugs, 2011, 29, 800-810.
68. Qin, Y.; Meng, L.; Hu, C.; Duan, W.; Zuo, Z.; Lin, L.; Zhang, X.; Ding, J. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol. Cancer. Ther., 2007, 6, 2429-2440.
69. Li, Y.; Luan, Y.; Qi, X.M.; Li, M.; Gong, L.K.; Xue, X.A.; Wu, X.F.; Wu, Y.F.; Chen, M.; Xing, G.Z.; Yao, J.; Ren, J. Emodin Triggers DNA Double-Strand Breaks by Stabilizing Topoisomerase II-DNA Cleavage Complexes and by Inhibiting ATP Hydrolysis of Topoisomerase II. Toxicol. Sci., 2010, 118, 435-443.
70. Kong, X.B.; Rubin, L.; Chen, L.I.; Ciszewska, G.; Watanabe, K.A.; Tong, W.P.; Sirotnak, F.M.; Chou, T.C. Topoisomerase Ii-Mediated DNA Cleavage Activity and Irreversibility of Cleavable Complex-Formation Induced by DNA Intercalator with Alkylating Capability. Mol. Pharmacol., 1992, 41, 237-244.
71. Roca, J.; Ishida, R.; Berger, J.M.; Andoh, T.; Wang, J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 1781-1785.
72. Tanabe, K.; Ikegami, Y.; Ishida, R.; Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res., 1991, 51, 4903-4908.
73. Hasinoff, B.B.; Herman, E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol., 2007, 7, 140-144.
74. Case, D.C.; Ervin, T.J.; Boyd, M.A.; Bove, L.G.; Sonneborn, H.L.; Paul, S.D. Phase-Ii Study of Aclarubicin in Acute Myeloblastic-Leukemia. Am. J. Clin. Oncol.-Canc., 1987, 10, 523-526.
75. Case, D.C.; Gams, R.; Ervin, T.J.; Boyd, M.A.; Oldham, F.B. Phase I-Ii Trial of High-Dose Epirubicin in Patients with Lymphoma. Cancer Res., 1987, 47, 6393-6396.
76. Chang, S.; Hu, T.; Hsieh, T.S. Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J. Biol. Chem., 1998, 273, 19822-19828.
77. Hu, T.; Sage, H.; Hsieh, T.S. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J. Biol. Chem., 2002, 277, 5944-5951.
78. Renodon-Corniere, A.; Jensen, L.H.; Nitiss, J.L.; Jensen, P.B.; Sehested, M. Analysis of bisdioxopiperazine Dexrazoxane binding to human DNA topoisomerase II alpha: Decreased binding as a mechanism of drug resistance. Biochemistry, 2003, 42, 9749-9754.
79. Sehested, M.; Wessel, I.; Jensen, L.H.; Holm, B.; Oliveri, R.S.; Kenwrick, S.; Creighton, A.M.; Nitiss, J.L.; Jensen, P.B. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res., 1998, 58, 1460-1468.
80. Wessel, I.; Jensen, L.H.; Jensen, P.B.; Falck, J.; Rose, A.; Roerth, M.; Nitiss, J.L.; Sehested, M. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res., 1999, 59, 3442-3450.
81. Wessel, I.; Jensen, L.H.; Renodon-Corniere, A.; Sorensen, T.K.; Nitiss, J.L.; Jensen, P.B.; Sehested, M. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Lett., 2002, 520, 161-166.
82. Huang, K.C.; Gao, H.; Yamasaki, E.F.; Grabowski, D.R.; Liu, S.; Shen, L.L.; Chan, K.K.; Ganapathi, R.; Snapka, R.M. Topoisomerase II poisoning by ICRF-193. J. Biol. Chem., 2001, 276, 44488-44494.
83. Oestergaard, V.H.; Knudsen, B.R.; Andersen, A.H. Dissecting the cellkilling mechanism of the topoisomerase II-targeting drug ICRF-193. J. Biol. Chem., 2004, 279, 28100-28105.
84. Jensen, L.H.; Nitiss, K.C.; Rose, A.; Dong, J.; Zhou, J.; Hu, T.; Osheroff, N.; Jensen, P.B.; Sehested, M.; Nitiss, J.L. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J. Biol. Chem., 2000, 275, 2137-2146.
85. Kobayashi, M.; Adachi, N.; Aratani, Y.; Kikuchi, A.; Koyama, H. Decreased topoisomerase II alpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett., 2001, 166, 71-77.
86. Grauslund, M.; Thougaard, A.V.; Fuchtbauer, A.; Hofland, K.F.; Hjorth, P.H.; Jensen, P.B.; Sehested, M.; Fuchtbauer, E.M.; Jensen, L.H. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Mol. Pharmacol., 2007, 72, 1003-1014.
87. Hasinoff, B.B.; Abram, M.E.; Barnabe, N.; Khelifa, T.; Allan, W.P.; Yalowich, J.C. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol. Pharmacol., 2001, 59, 453-461.
88. Fortune, J.M.; Osheroff, N. Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage. J. Biol. Chem., 1998, 273, 17643-17650.
89. Dimaggio, J.J.; Warrell, R.P., Jr.; Muindi, J.; Stevens, Y.W.; Lee, S.J.; Lowenthal, D.A.; Haines, I.; Walsh, T.D.; Baltzer, L.; Yaldaei, S. Phase I clinical and pharmacological study of merbarone. Cancer Res., 1990, 50, 1151-1155.
90. Malik, U.R.; Dutcher, J.P.; Caliendo, G.; Lasala, P.; Mitnick, R.; Wiernik, P.H. Phase II trial of merbarone in patients with malignant brain tumors. Med. Oncol., 1997, 14, 159-162.
91. Drake, F.H.; Hofmann, G.A.; Mong, S.M.; Bartus, J.O.; Hertzberg, R.P.; Johnson, R.K.; Mattern, M.R.; Mirabelli, C.K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res., 1989, 49, 2578-2583.
92. Drake, F.H.; Hofmann, G.A.; Bartus, H.F.; Mattern, M.R.; Crooke, S.T.; Mirabelli, C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 1989, 28, 8154-8160.
93. Chen, M.; Beck, W.T. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res., 1995, 55, 1509-1516.
94. Khelifa, T.; Beck, W.T. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol. Pharmacol., 1999, 55, 548-556.
95. Ranise, A.; Spallarossa, A.; Schenone, S.; Bruno, O.; Bondavalli, F.; Pani, A.; Marongiu, M.E.; Mascia, V.; La Colla, P.; Loddo, R. Synthesis and antiproliferative activity of basic thioanalogs of merbarone. Bioorg. Med. Chem., 2003, 11, 2575-2589.
96. Natale, R.B.; Cody, R.L.; Simon, M.S.; Wheeler, R.H. An Invivo and Invitro Trial of Aclarubicin in Metastatic Breast-Cancer -A Novel-Approach to the Study of Analogs. Cancer Chemoth. Pharm., 1993, 31, 485-488.
97. Sorensen, B.S.; Sinding, J.; Andersen, A.H.; Alsner, J.; Jensen, P.B.; Westergaard, O. Mode of Action of Topoisomerase-Ii-Targeting Agents at a Specific DNA-Sequence -Uncoupling the DNA-Binding, Cleavage and Religation Events. J. Mol. Biol., 1992, 228, 778-786.
98. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56, 185-229.
99. Nitiss, J.L.; Pourquier, P.; Pommier, Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res., 1997, 57, 4564-4569.
100. Hajji, N.; Mateos, S.; Pastor, N.; Dominguez, I.; Cortes, F. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat. Res.-Gen. Tox. En., 2005, 583, 26-35.
101. Bojanowski, K.; Lelievre, S.; Markovits, J.; Couprie, J.; Jacquemin-Sablon, A.; Larsen, A.K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 3025-3029.
102. McGeary, R.P.; Bennett, A.J.; Tran, Q.B.; Cosgrove, K.L.; Ross, B.P. Suramin: Clinical Uses and Structure-Activity Relationships. Mini-Rev. Med. Chem., 2008, 8, 1384-1394.
103. Grossman, S.A.; Phuphanich, S.; Lesser, G.; Rozental, J.; Grochow, L.B.; Fisher, J.; Piantadosi, S. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J. Clin. Oncol., 2001, 19, 3260-3266.
104. Calvo, E.; Cortes, J.; Rodriguez, J.; Sureda, M.; Beltran, U.; Rebollo, J.; Martinez-Monge, R.; Berian, J.M.; de Irala, J.; Brugarolas, A. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma -A multicenter phase II study. Cancer, 2001, 92, 2435-2443.
105. Song, S.H.; Wientjes, M.G.; Walsh, C.; Au, J.L.S. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res., 2001, 61, 6145-6150.
106. Zhang, Y.L.; Song, S.H.; Yang, F.; Au, J.L.S.; Wientjes, M.G. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J. Pharm. Exp. Ther., 2001, 299, 426-433.